United States - English - NLM (National Library of Medicine)

sunrise pharmaceutical, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2) ] sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the pract

United States - English - NLM (National Library of Medicine)

eci pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1meq po

United States - English - NLM (National Library of Medicine)

epic pharma, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 4.1 meq in 1 g - sodium polystyrene sulfonate powder, for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate powder, for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate powder, for suspension is contraindicated in patients with the following conditions: risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate powder, for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate powder, for suspension is expected to bind potassium at the practical exchange ratio of 1meq potassium per 1 gram of resin. in neonates, sodium polystyrene sulfonate powder, for suspension should not be given by the oral route. in both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate powder, for suspension use [see warnings and precautions (5.4)] .

United States - English - NLM (National Library of Medicine)

cmp pharma, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 1 g in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate for suspension is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate for suspension is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate for suspension is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfona

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 200 mg in 5 ml - amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus species (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, staphylococcus spp., or h. influenzae . triple therapy for helicobacter pylori with clarithromycin and lansoprazole: am

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 875 mg - amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of streptococcus species. (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis. amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli. amoxicillin tablets are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), s. pneumoniae, s

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9) - amoxicillin anhydrous 250 mg - amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus species (α- and β-hemolytic isolates only), streptococcus pneumoniae , staphylococcus spp., or haemophilus influenzae . amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli, proteus mirabilis , or enterococcus faecalis . amoxicillin capsules, amoxicillin for oral suspension, amoxicillin tablets (chewable) are indicated in the treatment of infections due to susceptible (only β-lactamase-negative) isolates of streptococcus spp. (α- and β-hemolytic isolates only), staphylococcus spp., or e. coli . amoxicillin capsules, amoxi

United States - English - NLM (National Library of Medicine)

rebel distributors corp. - amoxicillin (unii: 804826j2hu) (amoxicillin - unii:804826j2hu), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 400 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: lower respiratory tract infections – caused by β-lactamaseproducing strains of h. influenzae and m. catarrhalis. otitis media – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. sinusitis – caused by β-lactamase-producing strains of h. influenzae and m. catarrhalis. skin and skin structure infections – caused by β-lactamaseproducing strains of s. aureus, e. coli and klebsiella spp. urinary tract infections – caused by β-lactamase-producing strains of e. coli, klebsiella spp. and enterobacter spp. while amoxicillin and clavulanate potassium for oral suspension and chewable tablets are indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to amoxicillin and clavulanate potassium for oral suspensi

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - amoxicillin sodium - powder for solution for injection - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - amoxicillin sodium - powder for solution for injection - 500mg